Drugs / CT38
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03613129 Comparator | Jul 2018 → Apr 2019 | myalgic encephalomeyelitis/chronic fatigue syndrome | LUCINDA BATEMAN, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT38 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03613129 ↗ |
| Modality | Peptide | “CT38, an experimental peptide administered by subcutaneous infusion” NCT03613129 ↗ |